Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.
Erica C NakajimaAmber L SimpsonJan BogaertsElisabeth G E de VriesRichard Kinh Gian DoElena GarraldaGregory GoldmacherPaul E KinahanPhilippe LambinBarbara LeStageQin LiFrank Po-Yen LinSaskia LitièreRaquel Perez-LopezNicholas PetrickLawrence SchwartzLesley SeymourLalitha ShankarScott A LauriePublished in: JCO precision oncology (2024)
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.
Keyphrases
- lymph node metastasis
- clinical trial
- palliative care
- contrast enhanced
- healthcare
- squamous cell carcinoma
- public health
- deep learning
- magnetic resonance imaging
- electronic health record
- clinical practice
- magnetic resonance
- human health
- open label
- optical coherence tomography
- convolutional neural network
- climate change
- big data
- study protocol